AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15731325 — intervention group
Group type: EXPERIMENTAL
Intervention: Subarachnoid block with 2.5 mg hyperbaric bupivacaine + 25 mug fentanyl + 1 mL 10% glucose (Group S)
Number of subjects: 111
Study 15731325 — intervention group
Group type: COMPARATOR
Intervention: Pudendal nerve block with 7 mL 2% mepivacaine (Group P)
Number of subjects: 111
Study 15731325 — intervention group
Group type: EXPERIMENTAL
Intervention: Subarachnoid block (Group S)
Number of subjects: 111
Study 15731325 — intervention group
Group type: COMPARATOR
Intervention: Pudendal nerve block (Group P)
Number of subjects: 111
Study 15731325 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 111
Study 12373268 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) 1000 microg
Number of subjects: 32
Study 12373268 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) 100 microg
Number of subjects: 32
Study 12373268 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) 250 microg
Number of subjects: 32
Study 9437379 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole
Number of subjects: 100
Study 9437379 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine
Number of subjects: 100
Study 7814237 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg vitamin C per day
Number of subjects: 57
Study 7814237 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study 2550176 — intervention group
Group type: EXPERIMENTAL
Intervention: nedocromil sodium (2 x 2 mg puffs twice a day)
Number of subjects: 159
Study 2550176 — intervention group
Group type: EXPERIMENTAL
Intervention: nedocromil sodium
Number of subjects: 159
Study 2550176 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 159
Study 368333 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (Dixarit) at a dose of up to 0.15 mg daily
Number of subjects: 0
Study 368333 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31524825 — intervention group
Group type: EXPERIMENTAL
Intervention: MICT (40min at 55‐60% of peak power output, PPO)
Number of subjects: 27
Study 31524825 — intervention group
Group type: EXPERIMENTAL
Intervention: HIIT (60 x 8s at 80‐90% of peak heart rate, 12s active recovery)
Number of subjects: 27
Study 31524825 — intervention group
Group type: EXPERIMENTAL
Intervention: HIIT + RT (HIIT + 8 whole‐body exercises: 1 set of 8‐12 repetitions)
Number of subjects: 27
Study 31524825 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 27
Study 27799203 — intervention group
Group type: EXPERIMENTAL
Intervention: ABX464 (50 mg) under fed conditions
Number of subjects: 48
Study 27799203 — intervention group
Group type: COMPARATOR
Intervention: ABX464 (50 mg) under fasted conditions
Number of subjects: 48
Study 27799203 — intervention group
Group type: EXPERIMENTAL
Intervention: ABX464 (50 mg)
Number of subjects: 48
Study 26761561 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised, moderate-intensity physical exercise (exercise group; EG)
Number of subjects: 54
Study 26761561 — intervention group
Group type: COMPARATOR
Intervention: Normal daily physical activity (usual group; UG)
Number of subjects: 54
Study 25196628 — intervention group
Group type: COMPARATOR
Intervention: Traditional marking technique (Group A)
Number of subjects: 80
Study 25196628 — intervention group
Group type: EXPERIMENTAL
Intervention: New marking method (Group B)
Number of subjects: 80
Study 21504485 — intervention group
Group type: EXPERIMENTAL
Intervention: CF101 (2 mg)
Number of subjects: 75
Study 21504485 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 19910566 — intervention group
Group type: EXPERIMENTAL
Intervention: bicarbonate-buffered peritoneal dialysis solution (bicPDF)
Number of subjects: 55
Study 19910566 — intervention group
Group type: COMPARATOR
Intervention: standard lactate-buffered peritoneal dialysis fluid (SPDF)
Number of subjects: 55
Study 17488352 — intervention group
Group type: EXPERIMENTAL
Intervention: New algorithm (ICAD)
Number of subjects: 712
Study 17488352 — intervention group
Group type: COMPARATOR
Intervention: Standard algorithm (TRODIS)
Number of subjects: 712
Study 15515332 — intervention group
Group type: EXPERIMENTAL
Intervention: Enamel matrix derivative (EMD)
Number of subjects: 48
Study 15515332 — intervention group
Group type: COMPARATOR
Intervention: Bioabsorbable guided tissue regeneration (GTR) barrier (membrane)
Number of subjects: 48
Study 11373259 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (n = 109) - seven brief intervention sessions
Number of subjects: 296
Study 11373259 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B (n = 99) - three brief intervention sessions
Number of subjects: 296
Study 11373259 — intervention group
Group type: COMPARATOR
Intervention: Control group C (n = 88) - informed of risks and advised to reduce drinking
Number of subjects: 296
Study 9633727 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone + Azathioprine (PRED + AZA)
Number of subjects: 34
Study 9633727 — intervention group
Group type: COMPARATOR
Intervention: Prednisolone + Placebo (PRED + PLAC)
Number of subjects: 34
Study 8150100 — intervention group
Group type: EXPERIMENTAL
Intervention: Flutamide (250 mg two times per day for 9 months)
Number of subjects: 20
Study 8150100 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone (100 mg for 9 months)
Number of subjects: 20
Study 2894493 — intervention group
Group type: EXPERIMENTAL
Intervention: Red wine
Number of subjects: 19
Study 2894493 — intervention group
Group type: COMPARATOR
Intervention: Vodka
Number of subjects: 19
Study 29578097 — intervention group
Group type: EXPERIMENTAL
Intervention: Two doses of HPV vaccine (1-180 days)
Number of subjects: 1795
Study 29578097 — intervention group
Group type: COMPARATOR
Intervention: Three doses of HPV vaccine (1-60-180 days)
Number of subjects: 1795
Study 28688643 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine patch applied around the surgical wound
Number of subjects: 60
Study 28688643 — intervention group
Group type: COMPARATOR
Intervention: Control group with adhesive sides of the lidocaine patches shielded with waterproof films
Number of subjects: 60
Study 25878309 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-dimensional imaging and templating with standard instrumentation
Number of subjects: 46
Study 25878309 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-dimensional imaging and templating with patient-specific instrumentation
Number of subjects: 46
Study 25878309 — intervention group
Group type: COMPARATOR
Intervention: Two-dimensional imaging and standard instrumentation (historical control)
Number of subjects: 46
Study 22612364 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg/mL rhPDGF-BB
Number of subjects: 135
Study 22612364 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 mg/mL rhPDGF-BB
Number of subjects: 135
Study 22612364 — intervention group
Group type: COMPARATOR
Intervention: Scaffold control group
Number of subjects: 135
Study 20979997 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant luteinizing hormone (LH) luteal supplementation
Number of subjects: 0
Study 20979997 — intervention group
Group type: COMPARATOR
Intervention: Standard luteal P protocol
Number of subjects: 0
Study 20979997 — intervention group
Group type: COMPARATOR
Intervention: Both groups (Recombinant LH and Standard luteal P protocol)
Number of subjects: 0
Study 18364502 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV testing (cutoff of 1 pg/mL)
Number of subjects: 49196
Study 18364502 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV testing (cutoff of 2 pg/mL)
Number of subjects: 49196
Study 18364502 — intervention group
Group type: COMPARATOR
Intervention: Conventional cytology
Number of subjects: 49196
Study 16293958 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized flunisolide (1 mg) + salbutamol/ipratropium bromide (1,875/375 microg) b.i.d.
Number of subjects: 114
Study 12749746 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor (G-CSF)
Number of subjects: 326
Study 12749746 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte-macrophage colony-stimulating factor (GM-CSF)
Number of subjects: 326
Study 12749746 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 326
Study 15230212 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-phases cardiac rehabilitation program (Study Group, GB)
Number of subjects: 71
Study 15230212 — intervention group
Group type: COMPARATOR
Intervention: No participation in phase III of the program (Control Group, GK)
Number of subjects: 71
Study 10080566 — intervention group
Group type: EXPERIMENTAL
Intervention: D-cycloserine 100 mg/day
Number of subjects: 17
Study 7744141 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoladex 10.8-mg depot administered every 12 weeks
Number of subjects: 0
Study 7744141 — intervention group
Group type: COMPARATOR
Intervention: Zoladex 3.6-mg depot administered every 28 days
Number of subjects: 0
Study 2405137 — intervention group
Group type: COMPARATOR
Intervention: Control period (6 months) before the initiation of vitamin D therapy
Number of subjects: 0
Study 2405137 — intervention group
Group type: COMPARATOR
Intervention: Calculated creatinine clearance (glomerular filtration rate)
Number of subjects: 0
Study 2405137 — intervention group
Group type: COMPARATOR
Intervention: Serum osteocalcin
Number of subjects: 0
Study 2405137 — intervention group
Group type: COMPARATOR
Intervention: Serum concentrations of alkaline phosphatase, parathyroid hormone, and bicarbonate
Number of subjects: 0
Study 7390892 — intervention group
Group type: COMPARATOR
Intervention: Split-course irradiation
Number of subjects: 235
Study 7390892 — intervention group
Group type: COMPARATOR
Intervention: Continuous-course irradiation
Number of subjects: 235
Study 31977628 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.04 μg/kg/min norepinephrine infusion
Number of subjects: 99
Study 31977628 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05 μg/kg/min norepinephrine infusion
Number of subjects: 99
Study 31977628 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.06 μg/kg/min norepinephrine infusion
Number of subjects: 99
Study 31977628 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.07 μg/kg/min norepinephrine infusion
Number of subjects: 99
Study 31977628 — intervention group
Group type: COMPARATOR
Intervention: 0 μg/kg/min norepinephrine infusion (control)
Number of subjects: 99
Study 31977628 — intervention group
Group type: EXPERIMENTAL
Intervention: Norepinephrine ED50
Number of subjects: 99
Study 31977628 — intervention group
Group type: EXPERIMENTAL
Intervention: Norepinephrine ED80
Number of subjects: 99
Study 31977628 — intervention group
Group type: EXPERIMENTAL
Intervention: Norepinephrine ED95
Number of subjects: 99
Study 31977628 — intervention group
Group type: EXPERIMENTAL
Intervention: Apgar scores or umbilical arterial pH
Number of subjects: 99
Study 30477937 — intervention group
Group type: EXPERIMENTAL
Intervention: Regorafenib (160 mg/day for 21 of 28 days)
Number of subjects: 43
Study 30477937 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 30477937 — intervention group
Group type: EXPERIMENTAL
Intervention: Regorafenib
Number of subjects: 43
Study 28342829 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive peer mentoring (weekly meetings during inpatient stay and weekly contact for 90 days postdischarge)
Number of subjects: 158
Study 28342829 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive peer mentoring
Number of subjects: 158
Study 28342829 — intervention group
Group type: COMPARATOR
Intervention: Nonexperimental group (services only on request)
Number of subjects: 158
Study 25592552 — intervention group
Group type: EXPERIMENTAL
Intervention: CABG with left ventricular reconstruction
Number of subjects: 714
Study 25592552 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy
Number of subjects: 714
Study 25592552 — intervention group
Group type: COMPARATOR
Intervention: CABG
Number of subjects: 714
Study 23423576 — intervention group
Group type: EXPERIMENTAL
Intervention: Teplizumab
Number of subjects: 43
Study 23423576 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 21459838 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep
Number of subjects: 0
Study 21459838 — intervention group
Group type: COMPARATOR
Intervention: Time awake
Number of subjects: 0
Study 21459838 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast sleep spindles over the left superior parietal cortex
Number of subjects: 0
Study 18547941 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure Support Ventilation (PSV)
Number of subjects: 14
Study 18547941 — intervention group
Group type: COMPARATOR
Intervention: Volume-cycled Synchronized Intermittent Mandatory Ventilation (SIMV)
Number of subjects: 14
Study 17387223 — intervention group
Group type: EXPERIMENTAL
Intervention: Yttrium-90 ibritumomab tiuxetan (single dose)
Number of subjects: 104
Study 15376208 — intervention group
Group type: COMPARATOR
Intervention: Farming population
Number of subjects: 2106
Study 15376208 — intervention group
Group type: COMPARATOR
Intervention: Atopic asthma among farmers
Number of subjects: 2106
Study 15376208 — intervention group
Group type: COMPARATOR
Intervention: Non-atopic asthma among farmers
Number of subjects: 2106
Study 12808776 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose oxytocin (starting at 10 mIU/minute)
Number of subjects: 258
Study 12808776 — intervention group
Group type: COMPARATOR
Intervention: Low dose oxytocin (starting at 4 mIU/minute)
Number of subjects: 258
Study 12808776 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (high and low dose)
Number of subjects: 258
Study 9474311 — intervention group
Group type: EXPERIMENTAL
Intervention: Peribulbar anaesthesia
Number of subjects: 40
Study 9474311 — intervention group
Group type: COMPARATOR
Intervention: Retrobulbar anaesthesia
Number of subjects: 40
Study 7940435 — intervention group
Group type: EXPERIMENTAL
Intervention: Breathing air
Number of subjects: 9
Study 7940435 — intervention group
Group type: COMPARATOR
Intervention: Breathing 28% oxygen
Number of subjects: 9
Study 29447735 — intervention group
Group type: EXPERIMENTAL
Intervention: CABG
Number of subjects: 1905
Study 29447735 — intervention group
Group type: COMPARATOR
Intervention: PCI
Number of subjects: 1905
Study 27102726 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flow nasal cannula (HFNC)
Number of subjects: 36
Study 27102726 — intervention group
Group type: COMPARATOR
Intervention: Low-flow oxygen delivery (Control)
Number of subjects: 36
Study 25622729 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid cycle (voluntary arm exercise combined with FES-induced leg exercise)
Number of subjects: 20
Study 25622729 — intervention group
Group type: COMPARATOR
Intervention: Handcycle
Number of subjects: 20
Study 25622729 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 20
Study 23052930 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based virtual cycling training (hVCT)
Number of subjects: 27
Study 23052930 — intervention group
Group type: COMPARATOR
Intervention: Control program
Number of subjects: 27
Study 22170173 — intervention group
Group type: EXPERIMENTAL
Intervention: Variable flow group (VF)
Number of subjects: 40
Study 22170173 — intervention group
Group type: COMPARATOR
Intervention: Continuous flow group (CF)
Number of subjects: 40
Study 18223611 — intervention group
Group type: EXPERIMENTAL
Intervention: DAG
Number of subjects: 7
Study 18223611 — intervention group
Group type: COMPARATOR
Intervention: TAG
Number of subjects: 7
Study 17012095 — intervention group
Group type: EXPERIMENTAL
Intervention: Psycho-education (PE) program (four 60-minute weekly manual driven sessions)
Number of subjects: 67
Study 17012095 — intervention group
Group type: COMPARATOR
Intervention: Wait-list (WL) control group
Number of subjects: 67
Study 14668771 — intervention group
Group type: EXPERIMENTAL
Intervention: SPECT imaging after sublingual administration of 10 mg isosorbide dinitrate
Number of subjects: 36
Study 14668771 — intervention group
Group type: COMPARATOR
Intervention: Baseline tetrofosmin SPECT
Number of subjects: 36
Study 14668771 — intervention group
Group type: EXPERIMENTAL
Intervention: SPECT imaging after nitrate administration
Number of subjects: 36
Study 14668771 — intervention group
Group type: EXPERIMENTAL
Intervention: Concordance between tetrofosmin SPECT and PET
Number of subjects: 36
Study 10907385 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A reconstituted in lidocaine with epinephrine
Number of subjects: 10
Study 10907385 — intervention group
Group type: COMPARATOR
Intervention: Botulinum toxin type A reconstituted in saline
Number of subjects: 10
Study 8601885 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravascular ultrasonography (IVUS)
Number of subjects: 40
Study 8601885 — intervention group
Group type: COMPARATOR
Intervention: Intraarterial digital subtraction angiography (IA DSA) only
Number of subjects: 40
Study 1279279 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoprenaline (ISO) 1 microgram/min via intravenous infusion
Number of subjects: 9
Study 1279279 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepindolol TSD patches
Number of subjects: 9
Study 1279279 — intervention group
Group type: COMPARATOR
Intervention: Placebo TSD patches
Number of subjects: 9
Study 3905070 — intervention group
Group type: COMPARATOR
Intervention: 2 g cefoxitin i.v. in the preoperative period
Number of subjects: 155
Study 3905070 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g cefoxitin i.v. in the preoperative period + T tube suction drainage
Number of subjects: 155
Study 3905070 — intervention group
Group type: COMPARATOR
Intervention: T tube suction drainage only
Number of subjects: 155
Study 30517731 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean-Style Eating Pattern with 500 g/wk of lean unprocessed red meat (Med-Red Pattern)
Number of subjects: 41
Study 30517731 — intervention group
Group type: COMPARATOR
Intervention: Mediterranean-Style Eating Pattern with 200 g/wk of lean unprocessed red meat (Med-Control Pattern)
Number of subjects: 41
Study 30517731 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean-Style Eating Pattern (both Med-Red and Med-Control)
Number of subjects: 41
Study 26947568 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient protocol for weaning from tube to oral feeding (6-month program)
Number of subjects: 21
Study 26947568 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline
Number of subjects: 21
Study 24882900 — intervention group
Group type: EXPERIMENTAL
Intervention: Eszopiclone (ESZ) 3 mg plus naproxen 500 mg BID
Number of subjects: 52
Study 24882900 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus naproxen 500 mg BID
Number of subjects: 52
Study 22333698 — intervention group
Group type: EXPERIMENTAL
Intervention: MCC‐TT
Number of subjects: 0
Study 22333698 — intervention group
Group type: EXPERIMENTAL
Intervention: MCC‐CRM197
Number of subjects: 0
Study 22333698 — intervention group
Group type: EXPERIMENTAL
Intervention: MCC‐TT (after booster)
Number of subjects: 0
Study 22333698 — intervention group
Group type: EXPERIMENTAL
Intervention: MCC‐CRM197 (after booster)
Number of subjects: 0
Study 19798577 — intervention group
Group type: EXPERIMENTAL
Intervention: Circle of Life intervention
Number of subjects: 0
Study 18319360 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg immediate release 3 times daily for 7 days
Number of subjects: 24
Study 18319360 — intervention group
Group type: COMPARATOR
Intervention: 45 mg extended release once daily for 7 days
Number of subjects: 24
Study 18319360 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg propiverine intravenously
Number of subjects: 24
Study 18319360 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg immediate release administered at night
Number of subjects: 24
Study 15703362 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination tablet containing lamivudine, stavudine, and nevirapine (treatment A)
Number of subjects: 24
Study 15703362 — intervention group
Group type: COMPARATOR
Intervention: Separate marketed tablets administered simultaneously (treatment B)
Number of subjects: 24
Study 15703362 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination tablet (treatment A)
Number of subjects: 24
Study 15703362 — intervention group
Group type: COMPARATOR
Intervention: Separate marketed tablets (treatment B)
Number of subjects: 24
Study 15703362 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 24
Study 11990003 — intervention group
Group type: EXPERIMENTAL
Intervention: Protectamin (45 g daily for 2 weeks)
Number of subjects: 30
Study 11990003 — intervention group
Group type: EXPERIMENTAL
Intervention: Protectamin (45 g daily for 6 months)
Number of subjects: 30
Study 11990003 — intervention group
Group type: COMPARATOR
Intervention: Immunocal (45 g daily for 2 weeks)
Number of subjects: 30
Study 10418924 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 microg dose of PncT
Number of subjects: 0
Study 10418924 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 microg dose of PncT
Number of subjects: 0
Study 10418924 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 microg dose of PncT
Number of subjects: 0
Study 10418924 — intervention group
Group type: EXPERIMENTAL
Intervention: Booster response to three vaccine serotypes in the group primed with the lowest dose of conjugate vaccine (1 microg)
Number of subjects: 0
Study 7477168 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritonavir (various dosages)
Number of subjects: 62
Study 7477168 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritonavir (more sensitive assay in subgroup of 20 patients)
Number of subjects: 62
Study 7477168 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritonavir
Number of subjects: 62
Study 2147884 — intervention group
Group type: EXPERIMENTAL
Intervention: L-dropropizine
Number of subjects: 0
Study 2147884 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7444552 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-effort (LE) exercise training at 50% of maximal oxygen intake (HR 135 BPM)
Number of subjects: 13
Study 7444552 — intervention group
Group type: COMPARATOR
Intervention: High-effort (HE) exercise training at 80% of maximal oxygen intake (HR 170 BPM)
Number of subjects: 13
Study 31203203 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-assisted laparoscopic surgery
Number of subjects: 768
Study 31203203 — intervention group
Group type: COMPARATOR
Intervention: Laparotomy
Number of subjects: 768
Study 29280722 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored home modifications
Number of subjects: 92
Study 29280722 — intervention group
Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 92